The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I Study of Irinotecan (CPT-11), 5-FU, and Hydroxyurea with Radiation in Recurrent or Advanced Head and Neck Cancer.
 
Hiroyuki Uetake
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Yasunori Emi
Honoraria - Chugai Pharma
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takao Takahashi
Honoraria - Takeda
 
Takeshi Nagasaka
No Relationships to Disclose
 
Etsuro Hatano
Consulting or Advisory Role - Medicon
Speakers' Bureau - AMCo; Asahi Kasei; Astellas Pharma; Bayer; Chugai Pharma; Eisai; Johnson & Johnson; Kaken Pharmaceutical; Kyorin; Merck Serono; Nippon Kayaku; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Panasonic
 
Hitoshi Ojima
No Relationships to Disclose
 
Dai Manaka
No Relationships to Disclose
 
Tetsuya Kusumoto
No Relationships to Disclose
 
Yu Katayose
No Relationships to Disclose
 
Toshiyoshi Fujiwara
Research Funding - Astellas Pharma; Chugai Pharma; Shionogi; Taiho Pharmaceutical; Yakult Honsha
 
Kazuhiro Yoshida
Honoraria - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Chugai Pharma; Daiichi Sankyo; EA Pharma; Lilly Japan; Merck Serono; Novartis; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Michiaki Unno
Honoraria - Chugai Pharma; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Ichinosuke Hyodo
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Merck Serono (Inst); Takeda (Inst)
 
Naohiro Tomita
Research Funding - Chugai Pharma; Taiho Pharmaceutical
 
Kenichi Sugihara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; Novartis; Takeda
Research Funding - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Yoshihiko Maehara
Honoraria - Chugai Pharma
Research Funding - Chugai Pharma; Merck Serono; Yakult Honsha